BeOne continues to grow at a rapid pace with challenging and exciting opportunities for experienced professionals. When considering candidates, we look for scientific and business professionals who are highly motivated, collaborative, and most importantly, share our passionate interest in fighting cancer.
General Description:
We are seeking an experienced and collaborative OTC Team Lead to oversee and coordinate the full order-to-cash function within our Finance team. Reporting to the Global Process Owner, this role is responsible for the day-to-day leadership of OTC Specialists across four functional areas: AR & Cash Application, Credit Management & Underwriting, Collections & Dunning, etc.. The OTC Team Lead serves as the primary point of escalation for complex transactions, process exceptions, and cross-functional issues, while also driving process improvement and ensuring the team operates in accordance with company policy, internal controls, and applicable accounting standards. The ideal candidate is a seasoned OTC practitioner with emerging leadership experience, strong SAP S/4HANA proficiency, and the ability to develop talent while maintaining rigorous standards for accuracy, customer service, and compliance in a fast-growing biotech environment.
This role has hybrid work pattern, 3 days per week from our Warsaw office with 2 days remote.
Credit Management
Collections & Dunning
Credit Management
ERP & Systems
Education Required: Accounting / Business / Finance Bachelor's Degree
Requirements:
Travel: Minimum
Global Competencies
When we exhibit our values of Patients First, Driving Excellence, Bold Ingenuity, and Collaborative Spirit, through our twelve global competencies below, we help get more affordable medicines to more patients around the world.
We are proud to be an equal opportunity employer. BeOne does not discriminate on the basis of race, religion, color, sex, gender identity, sexual orientation, age, disability, national origin, veteran status or any other basis covered by appropriate law. All employment is decided on the basis of qualifications, merit, and business need.

Effective March 17, 2025, The U.S. subsidiary of BeiGene, Ltd. has changed its name to BeOne Medicines USA, Inc. This change comes ahead of our anticipated global rebranding to BeOne Medicines Ltd. and redomiciliation to Switzerland, pending shareholder approval. The new name reflects our commitment to develop innovative medicines and partner with the global community to help as many patients with cancer as possible.
To learn more about BeOne Medicines, please follow our new LinkedIn profile @BeOne Medicines.